TransMedics Group's trend of growing ROCE and increasing capital employed suggests profitable reinvestment opportunities, potentially leading to a multi-bagger performance. The stock's solid return to shareholders over the last three years indicates investor recognition of these changes.
$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks. Here are some top stocks in the sector climbing on drug trial and earnings news: $Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap. $Ligand Pharmaceuticals (LGND.US)$gained 23%...
Insider selling over the past year, particularly in recent months, may indicate insiders believe shares are overpriced. Despite some insider buying, the long-term outlook lacks positivity. Insider ownership shows alignment with shareholders, but past sales warrant caution.
TransMedics Group's significant top-line growth is undermined by its negative EBIT, liabilities outstripping cash and near-term receivables by $75m, and increased cash burn over the past year, constituting substantial risk.
Oppenheimer analysts hail TransMedics' recent quarter as 'blockbuster', emphasizing its long-term strategy to overcome short term challenges. The game-changing potential of the Organ Care System technology to reshape organ preservation and transport is also highlighted.
Positive interpretation of recent purchases at TransMedics Group amidst potential concerns over last year's sales. Insiders' stakes display alignment between management and smaller shareholders.
TransMedics股票討論區
$BJ批發俱樂部(BJ.US)$ 雖然沒有跌破止損,但在突破價位初期就出現大交易量派發,選擇提前清倉;
$CAVA Group(CAVA.US)$ 持有大約1個月,目前每週圖表相對10MA過度延伸,當前利潤已經超過25%,選擇賣出一半先鎖定一些利潤;
$NewAmsterdam Pharma(NAMS.US)$ 2個月左右的3T VCP 突破買入,價格很緊,交易量很乾,持倉佔比:3.79%;
$Vertex(VERX.US)$ 新高 回調後 緊密的 小基地突破買入,持倉佔比:3.4%;
$TransMedics(TMDX.US)$ 在GOOG和AFRM 每週圖表 圍繞上升趨勢的30MA附近的交易 工作不錯的基調下,本週圍繞每週圖表仍然處於上升趨勢的30MA買入了TMDX,它們的特點都是止損極小,但需要時間發揮作用,所以不會使用大的倉位,持倉佔比:4.35%;
2024第一季度已經結束,3天的長週末即將來臨,週末愉快🚴🏻
$Celsius Holdings(CELH.US)$ at $48 (this year) was the easiest money and people waited.
$Palantir(PLTR.US)$ at $14 was extremely undervalued and many waited
$Meta Platforms(META.US)$ was obvious to buy at $200 and everyone waited
$CrowdStrike(CRWD.US)$ was a clear buy at $150 and people waited
$TransMedics(TMDX.US)$ at $38 with a market cap of $1 Billion was a steal and nobody wanted to buy it.
Focus on the essentials: align...
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...
and why did this run up all on its own
暫無評論